3-Methyl-1-phenyl-2-pyrazolin-5-one (edaravone, Radicut injection) acts as an antioxidative radical scavenger, and has been developed as a treatment for cerebrovascular disease.
In addition, edaravone has been reported to have protective effects on functional damage caused by hyperglycemia to human dermal microvascular endothelial cells, 2) inflammation-induced pain 3) and cisplatin-induced nephrotoxicity in rats. 4) There are also many reports that edaravone has a protective effect on ischemic diseases caused by oxidative stress. Edaravone administration in patients with rheumatoid arthritis leads to a reduction in serum C-reactive protein and disease activity score. 5) Therefore, edaravone is expected to have a role in the prevention and treatment of acute and chronic diseases.
Transdermal absorption can be considered as an administration route for prolonged edaravone action. We have already reported the formation of an edaravone/cyclodextrin complex 6) and its skin permeability. 7) It has previously been clearly shown that the edaravone/cyclodextrin complex increases the amount of edaravone on the skin surface, as well as its skin permeability. These results suggest the possibility of transdermal and transmucosal treatment with edaravone. On the other hand, it has been reported that the pharmacokinetics of edaravone after intravenous administration in rats 8) and humans 9) involve excretion of glucuronide and sulfate. Moreover, the activity of UDP-glucuronosyltransferase (UGT) and sulfotransferase (SULT) in human skin has also been reported. [10] [11] [12] Therefore, it is considered that skin metabolism of edaravone in humans may be similar to that in rat skin. However, there have been no reports on skin metabolism of edaravone.
In this study, we used Wistar and hairless rat skin to investigate the metabolism of edaravone in vitro.
MATERIALS AND METHODS

Materials
Edaravone was synthesized from ethyl acetoacetate and phenylphydrazine according to the method of Komatu et al. 13) All other reagents and solvents were of special grade and used without further purification.
Animals Wistar/ST and hairless (HWY) male rats were obtained from Japan SLC (Shizuoka, Japan). These animals were housed in rooms controlled at 23Ϯ2°C and 55Ϯ15% relative humidity. Pelleted chow (Certified Rodent Diet #002; PMI Nutriton International, U.S.A.) and water were given ad libitum. 10-and 24-Week-old Wistar rats and 10-week-old hairless rats were used for experiments. All experiments were performed under the regulations of the Animal Ethical Committee of Mikasa Seiyaku (based on the Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry of Education, Culture, Science and Technology).
Residual Edaravone in Skin Homogenate and Intact Skin One gram of abdominal skin was excised from three or four 10-and 24-week-old Wistar or 10-week-old hairless rats, homogenized in 10 ml saline (Physcotron NS-50; Microtec, Chiba, Japan), and centrifuged at 10000 g for 20 min. The excised skin was stored at Ϫ80°C, and skin homogenate supernatant fluid was stored at Ϫ20°C until use. To establish whether the concentration of edaravone affected the level of edaravone in skin homogenate supernatant fluid, 0.05 ml edaravone solution (1.2 or 2.4 mmol/ml) was added to 0.95 ml 24-week-old Wistar rat skin homogenate supernatant fluid (60 or 120 nmol/ml final concentration). To assess whether rat strain had any effect on the decrease in edaravone in skin homogenate supernatant fluid, edaravone solution (0.05 ml, 2.4 mmol/ml) was added to 0.95 ml 10-week-old Wistar and hairless rat skin homogenate supernatant fluids (120 nmol/ml final concentration). These samples were incubated at 37°C. The intact skin was used and examined to consider the influence by homogenized the skin. In abdominal intact skin excised from four hairless rats, edaravone solution 0.05 ml (2.4 mmol/ml) was injected using a 1-ml syringe with a 25G needle. The intact skins were incubated at 37°C, then they were homogenized in methanol to inactivate the metabolic March 14, 2008 enzymes, and centrifuged at 3500 g for 20 min. Then, the residual amount of edarvone in these supernatant fluids was quantified by high performance liquid chromatography (HPLC).
The effect of pre-heating on the residual amount of edaravone in skin homogenate supernatant fluids was determined. In a study using four 10-week-old hairless rat skin homogenate supernatant fluids heated to 80°C, 0.05 ml edaravone solution (2.4 mmol/ml) was added to 0.95 ml supernatant fluid, and these samples were incubated at 37°C.
Furthermore, the samples in these examinations were mixed with methanol containing methylparaben (internal standard, IS) at 1 : 3, and these samples were quantified by HPLC.
Residual Edaravone in Plasma Three 10-week-old Wistar and hairless rats were used to determine the edaravone concentration in plasma. Plasma obtained from rat blood by centrifugation at 3500 g for 20 min was stored at Ϫ20°C until needed. After 0.05 ml edaravone solution (2.4 mmol/ml) was added to 0.9 ml plasma, the samples were incubated at 37°C. The amount of edaravone in the plasma was measured after mixing plasma and methanol (content IS) at a ratio of 1 : 3, and these samples were quantified by HPLC.
HPLC of Edaravone in Wistar and Hairless Rat Skin Homogenate Supernatant Fluids and Plasma
Residual edaravone in skin homogenate supernatant fluids and plasma was measured using the HPLC LC10 system (Shimadzu, Kyoto, Japan). Samples were analyzed on a 5-mm Inertsil ODS-2 column (4.6ϫ250 mm; GL Sciences, Tokyo, Japan), at a temperature of 40°C. Edaravone was detected by UV at 240 nm. The mobile phase consisted of a methanol : distilled water : acetic acid mixture (35 : 65 : 0.1, v/v). The flow rate of the mobile phase was 1 ml/min, and after methanol (content IS) was added to each sample, these samples 20 ml were injected onto the column. Residual edaravone ratio in these samples at each time was calculated by the following equation:
Comparison of HPLC of Edaravone in Wistar and Hairless Rat Skin Homogenate Supernatant Fluids
Samples were analyzed on a 5-mm Nucleosil 100 C18 column (4.6ϫ250 mm; GL Sciences), at a temperature of 40°C. To compare HPLC of edaravone in Wistar and hairless rat skin homogenate supernatant fluids, the mobile phase consisted of a mixture of methanol : 10 mmol sodium acetate (35 : 65, v/v, pH 5.5, adjusted with 10% acetic acid), 8) and the flow rate of the mobile phase was 0.5 ml/min.
Statistical Analysis Results were evaluated by the Tukey-Kramer test. pϽ0.05 was considered statistically significant.
RESULTS
HPLC of Edaravone in Wistar and Hairless Rat Skin Homogenate Supernatant Fluids and Plasma
The retention time of edaravone was 10 min. Over the concentration range 4.5-144 nmol/ml, HPLC demonstrated good linearity, with a correlation coefficient of Ͼ0.9999.
Residual Edaravone in Skin Homogenates and Intact Skin
The effect of edaravone concentration on the decrease in edaravone (60, 120 nmol/ml) in 24-week-old Wistar rat skin homogenate supernatant fluids is shown in Fig. 1 . The residual amount of edaravone in 24-week-old Wistar rat skin homogenate supernatant fluids decreased rapidly after addition of 0.05 ml edaravone solutions (1.2 or 2.4 mmol/ml). These results show that edaravone was metabolized in the skin homogenate supernatant fluids. The residual amount of edaravone in skin homogenate supernatant fluids decreased rapidly to ca. 40% after addition of edaravone. This decreased to ca. 10% at 37°C for 3 h.
Therefore, we investigated the residual amount of edaravone after a shorter period of time. The residual amount of edaravone in skin homogenate supernatant fluids from 10-and 24-week-old Wistar rats is shown in Fig. 2 point compared with that in 10-week-old rat skin homogenates, but the difference was not significant.
Hairless rats have been used in several experiments for transdermal drug delivery. Accordingly, we investigated hairless rat skin homogenate supernatant fluids. The residual amount of edaravone in skin homogenate supernatant fluids from 10-week-old hairless rats is shown in Fig. 3 . The residual amounts of edaravone in 10-week-old hairless rat skin homogenate supernatant fluids at 37°C at 0, 5 and 10 min were 50.19Ϯ14.17, 6.71Ϯ5.82 and 0.89Ϯ0.80, respectively, and edaravone was not detected after 20 min. The residual amount of edaravone in 10-week-old hairless rat skin homogenates decreased significantly compared with the residual amount of edaravone in 10-week-old Wistar rat skin homogenate supernatant fluids (pϽ0.05).
The residual amount of edaravone in intact skin is shown in Fig. 4 . The residual amount of edaravone did not differ significantly from that in skin homogenate supernatant fluids (unheated). The residual amounts of edaravone in hairless rat skin homogenate supernatant fluids heated to 80°C are shown in Fig. 5 . The decrease in the residual amount of edaravone was significantly less than that in unheated skin homogenate supernatant fluids (pϽ0.05).
Residual Edaravone in Plasma The residual amount of edaravone in plasma in 10-week-old Wistar and hairless rats is shown in Figs. 6A and B. The decrease in edaravone was slower than that in skin homogenate supernatant fluids at 37°C for 30 min. The residual amount of edaravone in Wistar and hairless rat plasma samples at each time point was significantly higher than that in the skin homogenate supernatant fluids of both rat types ( pϽ0.05). These results showed that metabolism of edaravone in plasma was low.
Comparison of Edaravone in Wistar and Hairless Rat Skin Homogenate Supernatant Fluids HPLC of edaravone standards and edaravone in Wistar and hairless rat skin homogenate supernatant fluids is shown in Fig. 7 . Peaks for edaravone appeared at around 20 min. Both rat skin homogenates incubated with edaravone at 37°C for 30 min had a t R value of 8.9 min; however, this t R value did not apply to skin homogenate supernatant fluids without edaravone. Hairless rat skin homogenate supernatant fluids incubated with edaravone had three different t R values of 8.9, 10 and 18 min, and these did not apply to the hairless rat skin homogenate supernatant fluids without edaravone. However, these t R values were not seen in the 80°C pre-heated skin homogenate 1152 Vol. 31, No. 6 supernatant fluids with edaravone (Fig. 8) .
DISCUSSION
Sulfoconjugation activity increases after birth and reaches a maximum in 3-week-old male and female rats. The activity in 2-year-old male and female rats is intermediate between the 7-week-old male and female rats, and no sex difference was observed. These results indicate that the substrates for sulfoconjugation can be divided into at least two groups, an alcohol and amine type, and a phenol type. 14) Moreover, it has already been reported for edaravone metabolism that the above is not first phase oxidation by P450, but rather secondphase metabolism, such as conjugation. 13) Our results suggest that edaravone is metabolized in skin homogenate supernatant fluids by second-phase metabolism. Edaravone concentration in the skin homogenate supernatant fluid decreased promptly after its addition, and was 40-60% of the amount added. Binding of edaravone to blood cells has previously been reported. 8) It is thought that this may be related to the binding of edaravone to cell membrane proteins. The HPLC t R values of edaravone in the skin homogenate supernatant fluids were compared with those previously reported, 8) and it was considered that the result of this examination represented the edaravone metabolite in the skin homogenate supernatant fluids. These results are shown in Table 1 .
Although further detailed examination is needed, it is thought that the metabolites of edaravone in the skin are probably glucuronide and sulfate, similar to those following intravenous administration of edaravone. The edaravone conjugates are glucuronide and sulfate, and it is reported that there is a lot of glucuronide and sulfate in bile and urine, respectively.
13) The UGT activity towards edaravone in the human liver and kidneys is high with UGT1A8, 1A1, 1A6, 1A7, 1A9, 1A10, 2B7 and 2B27, but there is no activity with UGT1A3, 1A4, 1A5, 2B4, 2B15 and 2B28. 15) In this study, the difference in the residual amount of edaravone in the skin homogenate supernatant fluids according to rat strain may be due to a difference in expression of the UGT family. In human skin, UGT has been shown to have activity against steroids 10) and androstanediol. 16) SULT has been shown to have activity against minoxidil in human scalp skin. 17) These findings suggest that human skin also has UGT and SULT activity. Although metabolic activity was reduced by methanol in this study, in order to investigate the influence of other substances it may be necessary to use alternative inhibitors of UGT or SULT. The effects of UGT inhibitors such as ketoconazole, 18) and SULT inhibitors such as curucmin and mefenamic acid 19, 20) have been reported. On the other hand, time 0 min in the residual ratio of each time is immediately after edaravone addition. It was thought that the residual ratio of edaravone was decreased at time 0 min by en- zymic and non-enzyme reactions. In addition, as shown in Fig. 5 , although it was thought that metabolic enzyme activity in skin homogenate supernatant fluids was inactivated by heat treatment at 80°C, the residual amount of edaravone in skin homogenate supernatant fluids decreased with time. Moreover, edaravone residual ratio in unheated skin homogenates decreased immediately after edaravone addition. Therefore, it was thought that involvement in enzymatic and non-enzymatic reaction, and the free radical may be related to the skin metabolism of edaravone. However, we thought that the results in different rats strains shown in Fig. 3 needed to be examined further. In this study, it was suggested that skin metabolism of edaravone had the necessity of consideration to conjugation by enzyme, and also a non-enzymatic reaction.
CONCLUSION
In this study, in vitro rat skin metabolism of edaravone appeared to lead to production of glucuronide and sulfate, although a detailed investigation is needed. However, it is suggested that edaravone metabolism in the skin is necessary for its effects on the expression of the UGT family and nonenzymatic reactions.
